Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
2001 1
2003 2
2004 2
2005 1
2006 2
2007 2
2009 2
2010 2
2013 4
2014 3
2015 3
2016 2
2017 3
2018 5
2019 5
2020 4
2021 4
2022 8
2023 13
2024 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens.
Podzamczer D, Imaz A, Lopez-Lirola A, Knobel H, Masiá M, Fanciulli C, Hernández C, Lagarde M, Gutierrez A, Curran A, Morano L, Montero-Alonso M, Troya J, Rigo R, Casadellà M, Navarro-Alcaraz A, Ardila F, Parera M, Bernal E, Echeverria P, Estrada V, Hidalgo-Tenorio C, Macias J, Prieto P, Portilla J, Valencia E, Vivancos MJ, Rivero A. Podzamczer D, et al. Among authors: montero alonso m. J Antimicrob Chemother. 2023 Nov 6;78(11):2696-2701. doi: 10.1093/jac/dkad285. J Antimicrob Chemother. 2023. PMID: 37725999 Clinical Trial.
IP-10 and MIG are sensitive markers of early virological response to HIV-1 integrase inhibitors.
Álvarez H, Gutiérrez-Valencia A, Mariño A, Saborido-Alconchel A, Calderón-Cruz B, Pérez-González A, Alonso-Domínguez J, Martínez-Barros I, Gallego-Rodríguez M, Moreno S, Aldamiz T, Montero-Alonso M, Bernal E, Galera C, Llibre JM, Poveda E. Álvarez H, et al. Among authors: montero alonso m. Front Immunol. 2023 Oct 18;14:1257725. doi: 10.3389/fimmu.2023.1257725. eCollection 2023. Front Immunol. 2023. PMID: 37920466 Free PMC article.
Povidone-Iodine as a Pre-Procedural Mouthwash to Reduce the Salivary Viral Load of SARS-CoV-2: A Systematic Review of Randomized Controlled Trials.
Garcia-Sanchez A, Peña-Cardelles JF, Ordonez-Fernandez E, Montero-Alonso M, Kewalramani N, Salgado-Peralvo AO, Végh D, Gargano A, Parra G, Guerra-Guajardo LI, Kozuma W. Garcia-Sanchez A, et al. Among authors: montero alonso m. Int J Environ Res Public Health. 2022 Mar 1;19(5):2877. doi: 10.3390/ijerph19052877. Int J Environ Res Public Health. 2022. PMID: 35270569 Free PMC article. Review.
Monocyte Activation and Ageing Biomarkers in the Development of Cardiovascular Ischaemic Events or Diabetes in People with HIV.
Bernardino JI, Alejos B, Rodriguez-Centeno J, Esteban-Cantos A, Mora-Rojas B, Montejano R, De Miguel R, Montero-Alonso M, Ayerdi O, Hernández-Gutierrez C, Curran A, Arribas JR, Rodés B; Cohort of the Spanish National AIDS Network (CoRIS). Bernardino JI, et al. Among authors: montero alonso m. Microorganisms. 2023 Jul 16;11(7):1818. doi: 10.3390/microorganisms11071818. Microorganisms. 2023. PMID: 37512990 Free PMC article.
A Randomized Trial of Dolutegravir Plus Darunavir/Cobicistat as a Switch Strategy in HIV-1-Infected Patients With Resistance to at Least 2 Antiretroviral Classes.
Santos JR, Domingo P, Portilla J, Gutiérrez F, Imaz A, Vilchez H, Curran A, Valcarce-Pardeiro N, Payeras A, Bernal E, Montero-Alonso M, Yzusqui M, Clotet B, Videla S, Moltó J, Paredes R. Santos JR, et al. Among authors: montero alonso m. Open Forum Infect Dis. 2023 Oct 31;10(11):ofad542. doi: 10.1093/ofid/ofad542. eCollection 2023 Nov. Open Forum Infect Dis. 2023. PMID: 38023553 Free PMC article.
Long-term evolution in liver disease markers and immune and lipid profiles in vertically HIV/HCV-coinfected youths with sustained viral response after direct-acting antivirals therapy.
Tarancon-Diez L, Carrasco I, Jiménez de Ory S, Berzosa Sánchez A, Hernanz-Lobo A, Montero-Alonso M, Laguno M, Bernardino JI, López-Cortés L, Aldamiz-Echevarría T, Collado P, Bisbal O, Samperiz G, Gavilán C, Ríos MJ, Ibarra S, Navarro ML, Muñoz-Fernández MÁ. Tarancon-Diez L, et al. Among authors: montero alonso m. Biomed Pharmacother. 2023 Jun;162:114587. doi: 10.1016/j.biopha.2023.114587. Epub 2023 Mar 30. Biomed Pharmacother. 2023. PMID: 37003032 Free article.
Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters.
Corona D, Pérez-Valero I, Camacho A, Gutiérrez Liarte Á, Montero-Alonso M, Alemán MR, Ruiz-Seco P, Pérez González A, Riera M, Jarrin I, Rivero-Juárez A, Rivero A. Corona D, et al. Among authors: montero alonso m. Int J Antimicrob Agents. 2024 Jan;63(1):107016. doi: 10.1016/j.ijantimicag.2023.107016. Epub 2023 Oct 26. Int J Antimicrob Agents. 2024. PMID: 37890734 Free article.
Factors associated with late presentation for HIV care in adolescents in Spain.
Epalza C, Domínguez-Rodríguez S, Cervantes E, Jiménez de Ory S, Frick MA, Fortuny C, Soler-Palacín P, Prieto-Tato L, Sainz T, Carreras-Abad C, Montero Alonso M, de Zárraga Fernández MA, Ocampo A, Rojo P, Navarro ML; Cohort of the Spanish HIV/AIDS Pediatric (CoRISpe)# and Adult (CoRIS) Networks. Epalza C, et al. Among authors: montero alonso m. HIV Med. 2022 Dec;23(11):1195-1201. doi: 10.1111/hiv.13407. Epub 2022 Sep 30. HIV Med. 2022. PMID: 36178091 Free article.
Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study.
Santos JR, Casadellà M, Noguera-Julian M, Micán-Rivera R, Domingo P, Antela A, Portilla J, Sanz J, Montero-Alonso M, Navarro J, Masiá M, Valcarce-Pardeiro N, Ocampo A, Pérez-Martínez L, García-Vallecillos C, Vivancos MJ, Imaz A, Iribarren JA, Hernández-Quero J, Villar-García J, Barrufet P, Paredes R; INSTINCT study group. Santos JR, et al. Among authors: montero alonso m. Front Cell Infect Microbiol. 2023 Jun 26;13:1187999. doi: 10.3389/fcimb.2023.1187999. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37434782 Free PMC article.
64 results